CGT
NBIX icon

Capital Guardian Trust’s Neurocrine Biosciences NBIX Stock Holding History

Capital Guardian Trust’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		$46.1M Buy
546,454
+9,574
+2% +$786K 0.62% 69
2019
Q1 		$47.3M Buy
536,880
+41,298
+8% +$3.45M 0.63% 67
2018
Q4 		$35.4M Buy
+495,582
New +$47.5M 0.56% 74

Other funds holding NBIX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Guardian Trust's NBIX Position: Q2 2019 in Review

Capital Guardian Trust increased its Neurocrine Biosciences (NBIX) stake by 1.8% in Q2 2019, buying an estimated $786K and bringing the position to 546,454 shares worth $46.1M. The position accounts for 0.62% of the portfolio, ranked #69.

Capital Guardian Trust first reported a position in NBIX in Q4 2018 and has held it in 3 quarters since. The position peaked at $47.3M in Q1 2019. 302 funds tracked by Wall St. Rank hold NBIX as of Q2 2019.

  • Capital Guardian Trust held 546,454 shares of Neurocrine Biosciences worth $46.1M as of Q2 2019.
  • Capital Guardian Trust bought 9,574 Neurocrine Biosciences shares in Q2 2019, an estimated $786K.
  • Neurocrine Biosciences made up 0.62% of Capital Guardian Trust's portfolio in Q2 2019, its #69 holding.
  • Capital Guardian Trust first reported a position in Neurocrine Biosciences in Q4 2018 and has held it in 3 quarters since.
  • Capital Guardian Trust's Neurocrine Biosciences position peaked at $47.3M in Q1 2019.
  • 302 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2019.

Based on Capital Guardian Trust's 13F filing for Q2 2019, filed 14 Aug 2019.